Spend :01 of your time each Monday morning as Twelve:01 delivers timely tools, trends, strategies, and/or compliance insights for the CME/CE enterprise.
In Rare Disease Advisor experts highlight how AI is reshaping rare disease research, from faster diagnosis to drug repurposing. By integrating genomics, imaging, and real-world data, AI reveals patterns invisible to traditional methods. For clinicians and learners, this signals a future where understanding AI outputs, weighing predictions, and integrating them into clinical reasoning stands to become part of evidence-driven care in the rare disease space
The August 2025 study “Establishing Organizational AI Governance in Healthcare” outlines how a Canadian hospital system used the People, Process, Technology, and Operations (PPTO) framework to formalize AI oversight across clinical and operational domains. It found inconsistent governance practices and highlighted the need for systemwide leadership and accountability. A companion survey conducted by the American Medical Association and reported on at the World Economic Forum showed that while most physicians value and use AI, nearly half want stronger governance protocols.
Even as federal healthcare innovation funds tighten, private capital is surging into digital health – especially AI. Reports from Rock Health, Silicon Valley Bank, Galen Growth, and the American Hospital Association all show 2025 as a year of fewer but larger evidence-driven deals. AI now commands more than 60% of healthcare tech funding, with investor confidence centering on clinical and operational solutions in oncology, mental health, and cardiovascular care.
